2023
Response to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect
Takahashi T, Stoiljkovic M, Song E, Gao X, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu Z, Kristant A, Zhang Y, Sulkowski P, Glazer P, Kaczmarek L, Horvath T, Iwasaki A. Response to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect. Neuron 2023, 111: 612-613. PMID: 36863323, DOI: 10.1016/j.neuron.2023.02.006.Peer-Reviewed Original Research
2022
LINE-1 activation in the cerebellum drives ataxia
Takahashi T, Stoiljkovic M, Song E, Gao XB, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu ZW, Kristant A, Zhang Y, Sulkowski P, Glazer PM, Kaczmarek LK, Horvath TL, Iwasaki A. LINE-1 activation in the cerebellum drives ataxia. Neuron 2022, 110: 3278-3287.e8. PMID: 36070749, PMCID: PMC9588660, DOI: 10.1016/j.neuron.2022.08.011.Peer-Reviewed Original ResearchConceptsLINE-1 activationL1 activationAtaxia telangiectasia patientsNuclear element-1Transposable elementsEpigenetic silencersHuman genomeL1 promoterMolecular regulatorsDNA damagePurkinje cell dysfunctionElement 1First direct evidenceTelangiectasia patientsDirect targetingCerebellar expressionNeurodegenerative diseasesDisease etiologyCalcium homeostasis
2021
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. Therapy for Alzheimer’s disease: Missing targets and functional markers? Ageing Research Reviews 2021, 68: 101318. PMID: 33711510, PMCID: PMC8131215, DOI: 10.1016/j.arr.2021.101318.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseNew symptomatic treatmentsNeural network integrityClinical characteristicsNext-generation therapiesSymptomatic treatmentOutcome biomarkerTau pathologyFluid biomarkersPlasma biomarkersDisease progressionEffective therapyNeurophysiological biomarkersTreatment candidatesCerebrospinal fluidNovel biomarkersTranslational studiesTreatment interventionsDiseaseTarget engagementTherapyBiomarkersCurrent conceptsMultiple biomarkersDrug targets
2015
Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays
Stoiljkovic M, Leventhal L, Chen A, Chen T, Driscoll R, Flood D, Hodgdon H, Hurst R, Nagy D, Piser T, Tang C, Townsend M, Tu Z, Bertrand D, Koenig G, Hajós M. Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays. Biochemical Pharmacology 2015, 97: 576-589. PMID: 26206187, DOI: 10.1016/j.bcp.2015.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAlpha7 Nicotinic Acetylcholine ReceptorAnimalsBehavior, AnimalCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugFemaleGene Expression RegulationHippocampusHumansLearningMaleMemoryMiceMice, Inbred C57BLOocytesProtein BindingQuinuclidinesRatsRats, Sprague-DawleyRats, WistarThiophenesXenopus laevisConceptsHippocampal theta oscillationsTheta oscillationsNeurophysiological assaysPro-cognitive effectsNovel object recognitionStimulation-induced hippocampal theta oscillationTheta oscillation powerWater T-mazeCognitive effectsNeurophysiological correlatesDose-dependent facilitationMemory acquisitionCognitive functionT-mazeObject recognitionΑ7 nAChRsHuman α7 nAChRConcentration-response relationshipSynaptic transmissionΑ7 nicotinic acetylcholine receptorSub-maximal concentrationsRat hippocampal slicesLong-term potentiationNicotinic acetylcholine receptorsOscillation power